- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...

INGELHEIM, Germany and RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 7, 2022 /PRNewswire/ -- The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant ...

The U.S. Food and Drug Administration has approved the use of Jardiance 10 mg and 25 mg tables to lower blood sugar along with diet and exercise in children aged 10 years and older with type 2 ...

Jardiance (empagliflozin) is a prescription drug that’s used to manage blood sugar levels and lower certain risks. The drug comes as an oral tablet. It’s usually taken once per day. The active ...

The European Commission approved JARDIANCE 10 and 25 mg once daily tablets for use when diet and exercise alone do not provide adequate glycemic control. JARDIANCE may be used alone when metformin is ...

(Reuters) - Two leading U.S. medical societies are poised in the coming weeks to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly ...

In a new chapter for the ongoing story of sodium glucose transporter-2 inhibitor (SGLT2) inhibitors, Boehringer Ingelheim International GmbH and Eli Lilly and Co.'s Jardiance (empagliflozin) has ...

Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors ...

Please provide your email address to receive an email when new articles are posted on . Jardiance had a 28% relative risk reduction for kidney disease progression vs. placebo. The drug also showed a ...

- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. Jardiance is not ...

European Commission approves third product from the Boehringer Ingelheim and Lilly Diabetes alliance RIDGEFIELD, Conn. and INDIANAPOLIS, May 23, 2014 /PRNewswire/ -- The European Commission granted ...